Pub Date : 2026-01-01DOI: 10.1016/j.lanmic.2025.101230
Lisa Bauer PhD , Lonneke Leijten BSc , Matteo Iervolino MSc , Varun Chopra MSc , Laura van Dijk MSc , Mark Power MSc , Willemijn Rijnink MSc , Mark Pronk BSc , Monique Spronken MSc , Mathis Funk PhD , Rory D de Vries PhD , Mathilde Richard PhD , Prof Thijs Kuiken PhD DVM , Debby van Riel PhD
<div><h3>Background</h3><div>Highly pathogenic avian influenza H5N1 viruses of the A/Goose/Guangdong/1/1996 lineage pose a global threat to wildlife, domestic animals, and humans. Cross-species transmission events to mammals, including humans, in the past 4 years highlight this threat. For influenza A viruses, crucial determinants of cross-species and intraspecies transmission to and among mammals include attachment to and replication in respiratory airway epithelial cells. Although these determinants have been studied for H5N1 viruses in the past, limited studies for clade 2.3.4.4b viruses exist. Therefore, the aim of this study was to determine the ability of recent clade 2.3.4.4b H5N1 viruses to attach to human respiratory tissues, to replicate in human airway epithelial cells and the associated immune response.</div></div><div><h3>Methods</h3><div>In this in-vitro study, we investigated three H5N1 clade 2.3.4.4b viruses (H5N1<sup>Gull2022</sup>, H5N1<sup>Polecat2022</sup>, and H5N1<sup>Bovine2024</sup>) in comparison with previously studied 2.1.3.2 H5N1 (H5N1<sup>2005</sup>) and a seasonal H3N2 virus. First, we compared virus attachment patterns by virus histochemistry. Second, we investigated the infection and replication efficiency, and innate immune responses in infected human respiratory epithelium in vitro. Third, we measured polymerase complex activity using a minigenome assay.</div></div><div><h3>Findings</h3><div>Clade 2.3.4.4b viruses and H5N1<sup>2005</sup> virus differed by five amino acids located near the receptor binding site of the haemagglutinin. All clade 2.3.4.4b viruses attached more efficiently to cells of the human upper and lower respiratory tract compared with H5N1<sup>2005</sup> virus. All clade 2.3.4.4b viruses replicated in human nasal and tracheobronchial respiratory epithelium cultures. In the tracheobronchial respiratory epithelium cultures, H5N1<sup>Gull20</sup><sup>2</sup><sup>2</sup> virus replicated more efficiently than H5N1<sup>2005</sup> virus (p=0·0050) and reached titres similar to H3N2<sup>2003</sup> virus. Polymerase complex activity of H5N1<sup>Gull2022</sup> virus was not significantly different from that of H5N1<sup>2005</sup> and was significantly lower compared with H3N2<sup>2003</sup> virus (p≤0·0001). Infection with H5N1<sup>Gull2022</sup> virus induced a broader antiviral immune response than H5N1<sup>2005</sup> virus.</div></div><div><h3>Interpretation</h3><div>Clade 2.3.4.4b H5N1 viruses have phenotypic characteristics that are different from a clade 2.1.3.2 H5N1<sup>2005</sup> virus. The ability of clade 2.3.4.4b viruses to attach to and replicate in respiratory epithelium likely contributes to an increased risk for both human infection and virus adaptation to humans.</div></div><div><h3>Funding</h3><div>The EU, the Dutch Research Council, the Netherlands Organization for Health Research and Development, and the Dutch Ministries of Agriculture, Fisheries, Food Security and Nature, and Health,
{"title":"Attachment and replication of clade 2.3.4.4b influenza A (H5N1) viruses in human respiratory epithelium: an in-vitro study","authors":"Lisa Bauer PhD , Lonneke Leijten BSc , Matteo Iervolino MSc , Varun Chopra MSc , Laura van Dijk MSc , Mark Power MSc , Willemijn Rijnink MSc , Mark Pronk BSc , Monique Spronken MSc , Mathis Funk PhD , Rory D de Vries PhD , Mathilde Richard PhD , Prof Thijs Kuiken PhD DVM , Debby van Riel PhD","doi":"10.1016/j.lanmic.2025.101230","DOIUrl":"10.1016/j.lanmic.2025.101230","url":null,"abstract":"<div><h3>Background</h3><div>Highly pathogenic avian influenza H5N1 viruses of the A/Goose/Guangdong/1/1996 lineage pose a global threat to wildlife, domestic animals, and humans. Cross-species transmission events to mammals, including humans, in the past 4 years highlight this threat. For influenza A viruses, crucial determinants of cross-species and intraspecies transmission to and among mammals include attachment to and replication in respiratory airway epithelial cells. Although these determinants have been studied for H5N1 viruses in the past, limited studies for clade 2.3.4.4b viruses exist. Therefore, the aim of this study was to determine the ability of recent clade 2.3.4.4b H5N1 viruses to attach to human respiratory tissues, to replicate in human airway epithelial cells and the associated immune response.</div></div><div><h3>Methods</h3><div>In this in-vitro study, we investigated three H5N1 clade 2.3.4.4b viruses (H5N1<sup>Gull2022</sup>, H5N1<sup>Polecat2022</sup>, and H5N1<sup>Bovine2024</sup>) in comparison with previously studied 2.1.3.2 H5N1 (H5N1<sup>2005</sup>) and a seasonal H3N2 virus. First, we compared virus attachment patterns by virus histochemistry. Second, we investigated the infection and replication efficiency, and innate immune responses in infected human respiratory epithelium in vitro. Third, we measured polymerase complex activity using a minigenome assay.</div></div><div><h3>Findings</h3><div>Clade 2.3.4.4b viruses and H5N1<sup>2005</sup> virus differed by five amino acids located near the receptor binding site of the haemagglutinin. All clade 2.3.4.4b viruses attached more efficiently to cells of the human upper and lower respiratory tract compared with H5N1<sup>2005</sup> virus. All clade 2.3.4.4b viruses replicated in human nasal and tracheobronchial respiratory epithelium cultures. In the tracheobronchial respiratory epithelium cultures, H5N1<sup>Gull20</sup><sup>2</sup><sup>2</sup> virus replicated more efficiently than H5N1<sup>2005</sup> virus (p=0·0050) and reached titres similar to H3N2<sup>2003</sup> virus. Polymerase complex activity of H5N1<sup>Gull2022</sup> virus was not significantly different from that of H5N1<sup>2005</sup> and was significantly lower compared with H3N2<sup>2003</sup> virus (p≤0·0001). Infection with H5N1<sup>Gull2022</sup> virus induced a broader antiviral immune response than H5N1<sup>2005</sup> virus.</div></div><div><h3>Interpretation</h3><div>Clade 2.3.4.4b H5N1 viruses have phenotypic characteristics that are different from a clade 2.1.3.2 H5N1<sup>2005</sup> virus. The ability of clade 2.3.4.4b viruses to attach to and replicate in respiratory epithelium likely contributes to an increased risk for both human infection and virus adaptation to humans.</div></div><div><h3>Funding</h3><div>The EU, the Dutch Research Council, the Netherlands Organization for Health Research and Development, and the Dutch Ministries of Agriculture, Fisheries, Food Security and Nature, and Health,","PeriodicalId":46633,"journal":{"name":"Lancet Microbe","volume":"7 1","pages":"Article 101230"},"PeriodicalIF":20.4,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145783207","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-01DOI: 10.1016/j.lanmic.2025.101243
Seshasailam Venkateswaran , Jessica Mitchell , Marieke Emonts , Mark Bradley , Nichola Hawkins , Andrew C Singer
{"title":"Diagnostics at the frontline: using the Public Accounts Committee report to catalyse the UK’s antimicrobial resistance diagnostics strategy","authors":"Seshasailam Venkateswaran , Jessica Mitchell , Marieke Emonts , Mark Bradley , Nichola Hawkins , Andrew C Singer","doi":"10.1016/j.lanmic.2025.101243","DOIUrl":"10.1016/j.lanmic.2025.101243","url":null,"abstract":"","PeriodicalId":46633,"journal":{"name":"Lancet Microbe","volume":"7 1","pages":"Article 101243"},"PeriodicalIF":20.4,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145114707","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-01DOI: 10.1016/j.lanmic.2025.101336
The Lancet Microbe
{"title":"We have the means to beat malaria, do we have the will?","authors":"The Lancet Microbe","doi":"10.1016/j.lanmic.2025.101336","DOIUrl":"10.1016/j.lanmic.2025.101336","url":null,"abstract":"","PeriodicalId":46633,"journal":{"name":"Lancet Microbe","volume":"7 1","pages":"Article 101336"},"PeriodicalIF":20.4,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145844235","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Editor note to PET-CT-guided characterisation of progressive, preclinical tuberculosis infection and its association with low-level circulating Mycobacterium tuberculosis DNA in household contacts in Leicester, UK: a prospective cohort study","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":46633,"journal":{"name":"Lancet Microbe","volume":"7 1","pages":"Article 101310"},"PeriodicalIF":20.4,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145996546","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Staphylococcus aureus bacteraemia presents a substantial clinical burden, with high rates of morbidity and mortality. Despite its severity, therapeutic advancements have been small in the past decade, prompting exploration of adjunctive treatment strategies against S aureus bacteraemia. Among these strategies, P2Y12 inhibitors have gained attention due to their potential antistaphylococcal and platelet-modulating effects. Preclinical studies suggest that ticagrelor enhances platelet-mediated bacterial killing and interferes with S aureus metabolism. Clinical data indicate a potential protective effect of ticagrelor in S aureus bacteraemia, as compared with that of clopidogrel. Nevertheless, clopidogrel itself appears to offer protective effects, when compared with no treatment. However, these findings are based exclusively on non-randomised studies conducted in individuals with cardiovascular disease. Two randomised trials currently in development could provide further evidence on the therapeutic role of P2Y12 inhibitors in S aureus bacteraemia. Future research should also focus on preventive strategies and identifying populations at high risk who could benefit from such interventions.
{"title":"P2Y12 inhibitors in Staphylococcus aureus bacteraemia: current evidence and clinical implications","authors":"Emanuele Rando MD , Luis Eduardo López-Cortés MD PhD , Prof Jesús Rodríguez-Baño","doi":"10.1016/j.lanmic.2025.101255","DOIUrl":"10.1016/j.lanmic.2025.101255","url":null,"abstract":"<div><div><em>Staphylococcus aureus</em> bacteraemia presents a substantial clinical burden, with high rates of morbidity and mortality. Despite its severity, therapeutic advancements have been small in the past decade, prompting exploration of adjunctive treatment strategies against <em>S aureus</em> bacteraemia. Among these strategies, P2Y12 inhibitors have gained attention due to their potential antistaphylococcal and platelet-modulating effects. Preclinical studies suggest that ticagrelor enhances platelet-mediated bacterial killing and interferes with <em>S aureus</em> metabolism. Clinical data indicate a potential protective effect of ticagrelor in <em>S aureus</em> bacteraemia, as compared with that of clopidogrel. Nevertheless, clopidogrel itself appears to offer protective effects, when compared with no treatment. However, these findings are based exclusively on non-randomised studies conducted in individuals with cardiovascular disease. Two randomised trials currently in development could provide further evidence on the therapeutic role of P2Y12 inhibitors in <em>S aureus</em> bacteraemia. Future research should also focus on preventive strategies and identifying populations at high risk who could benefit from such interventions.</div></div>","PeriodicalId":46633,"journal":{"name":"Lancet Microbe","volume":"7 1","pages":"Article 101255"},"PeriodicalIF":20.4,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145432532","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-01DOI: 10.1016/j.lanmic.2025.101263
Abena S Amoah PhD , Prof Selidji T Agnandji PhD , Michel Bengtson PhD , Jennifer A Downs PhD , Meral Esen MD , Jeevan Giddaluru PhD , Simon P Jochems PhD , Maria M M Kaisar PhD , Julia Makinde PhD , Mikhael D Manurung PhD , Prof Moustapha Mbow PhD , Gemma Moncunill PhD , Rajagopal Murugan PhD , Jacqueline Mutai PhD , Prof Helder I Nakaya PhD , Gyaviira Nkurunungi PhD , Magnus Palmblad PhD , Jeremia J Pyuza MD , Koen A Stam MSc , Wouter A A de Steenhuijsen Piters PhD , Gerhild Zauner
Vaccines have improved global health substantially, preventing millions of deaths worldwide. However, striking variations in the immunogenicity and efficacy of some vaccines persist across populations. Notably, suboptimal responses to some vaccines, also known as vaccine hyporesponsiveness, have been observed in low-income and middle-income countries (LMICs) compared with high-income countries or in rural areas within LMICs compared with urban areas within LMICs. Environmental factors, host genetics, lifestyle, and nutrition contribute to immunological variations influencing vaccine responses, highlighting the need to identify key immune signatures that can be manipulated to overcome vaccine hyporesponsiveness. The integration of diverse datasets, accelerated by artificial intelligence, is essential to achieve this goal, which is currently hampered by the under-representation of data from LMICs. The HypoVax Global knowledge hub aims to address this gap by fostering international collaboration and compiling globally representative immunological data from population studies and vaccine trials. The hub offers a platform for high-dimensional data analyses, promotes equitable partnerships, and strives to ensure that all contributions lead to context-specific insights that can inform immunisation strategies to ultimately overcome vaccine hyporesponsiveness.
{"title":"Tackling vaccine hyporesponsiveness through global collaboration, diverse population studies, and data integration","authors":"Abena S Amoah PhD , Prof Selidji T Agnandji PhD , Michel Bengtson PhD , Jennifer A Downs PhD , Meral Esen MD , Jeevan Giddaluru PhD , Simon P Jochems PhD , Maria M M Kaisar PhD , Julia Makinde PhD , Mikhael D Manurung PhD , Prof Moustapha Mbow PhD , Gemma Moncunill PhD , Rajagopal Murugan PhD , Jacqueline Mutai PhD , Prof Helder I Nakaya PhD , Gyaviira Nkurunungi PhD , Magnus Palmblad PhD , Jeremia J Pyuza MD , Koen A Stam MSc , Wouter A A de Steenhuijsen Piters PhD , Gerhild Zauner","doi":"10.1016/j.lanmic.2025.101263","DOIUrl":"10.1016/j.lanmic.2025.101263","url":null,"abstract":"<div><div>Vaccines have improved global health substantially, preventing millions of deaths worldwide. However, striking variations in the immunogenicity and efficacy of some vaccines persist across populations. Notably, suboptimal responses to some vaccines, also known as vaccine hyporesponsiveness, have been observed in low-income and middle-income countries (LMICs) compared with high-income countries or in rural areas within LMICs compared with urban areas within LMICs. Environmental factors, host genetics, lifestyle, and nutrition contribute to immunological variations influencing vaccine responses, highlighting the need to identify key immune signatures that can be manipulated to overcome vaccine hyporesponsiveness. The integration of diverse datasets, accelerated by artificial intelligence, is essential to achieve this goal, which is currently hampered by the under-representation of data from LMICs. The HypoVax Global knowledge hub aims to address this gap by fostering international collaboration and compiling globally representative immunological data from population studies and vaccine trials. The hub offers a platform for high-dimensional data analyses, promotes equitable partnerships, and strives to ensure that all contributions lead to context-specific insights that can inform immunisation strategies to ultimately overcome vaccine hyporesponsiveness.</div></div>","PeriodicalId":46633,"journal":{"name":"Lancet Microbe","volume":"7 1","pages":"Article 101263"},"PeriodicalIF":20.4,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145597750","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-01DOI: 10.1016/j.lanmic.2025.101228
Jill Hopkins MMedSc , Sue J Lee PhD , Naomi Waithira MSc , Chris Painter MSc , Clare L Ling PhD , Tamalee Roberts PhD , Thyl Miliya MD , Noah Obeng-Nkrumah PhD , Prof Japheth A Opintan PhD , Emmanuel P Abbeyquaye FWACP , Raph L Hamers MD , Yulia Rosa Saharman MD , Robert Sinto MD , Mulya Rahma Karyanti MD , R Fera Ibrahim MD , Samuel O Akech PhD , Prof Elizabeth A Ashley MRCP , Anousone Douangnouvong MD , Khamla Choumlivong MD , Prof Nicholas A Feasey PhD , Hong Phuong Trinh Thi
Background
Antimicrobial resistance (AMR) is a major global health threat, but there is scarcity of laboratory surveillance data linked to clinical information to determine burden and inform interventions, especially from low-income and middle-income countries. The ACORN2 study sought to address this through prospective case-based surveillance in 19 hospitals across Africa and Asia to characterise drug-resistant infections by origin, clinical syndrome, patient age, outcome, and geographical location.
Methods
Patients were enrolled on selected wards and clinical data were collected daily for community-acquired infections (CAIs). Point prevalence surveys for hospital-acquired infections (HAIs) were conducted weekly. Mortality was assessed at discharge and after 28 days. Linked microbiology data were extracted from local laboratory databases. Primary descriptive analyses focused on WHO Global Antimicrobial Resistance and Use Surveillance System pathogen (target organism) bloodstream infections (BSIs). Comparisons were adjusted for clustering by site using random effects models.
Findings
Over 31 months, 41 907 infections were characterised from 41 032 admissions. Two-thirds were children (19 351; 47·2%) or neonates (6649; 16·2%). There were marked differences in pathogen incidence and antibiotic resistance when clinical infections were stratified by patient age category and infection origin (CAI/HAI). The highest rates of target organism AMR BSI were third-generation cephalosporin-resistant (3GC-R) Escherichia coli (718·56/100 000 blood cultured infection episodes), meticillin-resistant Staphylococcus aureus (586·89/100 000 blood cultured infection episodes), and 3GC-R Klebsiella pneumoniae (364·92/100 000 blood cultured infection episodes). In-hospital mortality was 13·1% (166/1265) in patients with target organism BSI versus 6·2% (1357/21 845) in those with negative blood cultures, p<0·0001.
Interpretation
ACORN2 has shown practical implementation of collecting linked clinical-laboratory AMR data in low-income and middle-income countries and identified a significant burden of WHO GLASS BSI. Adoption of the ACORN2 approach at scale might enhance use of diagnostic microbiology and improve the volume of clinical data included in national and global AMR surveillance datasets.
{"title":"Prospective characterisation of drug-resistant bloodstream infections in Africa and Asia (ACORN2): a surveillance network assessment","authors":"Jill Hopkins MMedSc , Sue J Lee PhD , Naomi Waithira MSc , Chris Painter MSc , Clare L Ling PhD , Tamalee Roberts PhD , Thyl Miliya MD , Noah Obeng-Nkrumah PhD , Prof Japheth A Opintan PhD , Emmanuel P Abbeyquaye FWACP , Raph L Hamers MD , Yulia Rosa Saharman MD , Robert Sinto MD , Mulya Rahma Karyanti MD , R Fera Ibrahim MD , Samuel O Akech PhD , Prof Elizabeth A Ashley MRCP , Anousone Douangnouvong MD , Khamla Choumlivong MD , Prof Nicholas A Feasey PhD , Hong Phuong Trinh Thi","doi":"10.1016/j.lanmic.2025.101228","DOIUrl":"10.1016/j.lanmic.2025.101228","url":null,"abstract":"<div><h3>Background</h3><div>Antimicrobial resistance (AMR) is a major global health threat, but there is scarcity of laboratory surveillance data linked to clinical information to determine burden and inform interventions, especially from low-income and middle-income countries. The ACORN2 study sought to address this through prospective case-based surveillance in 19 hospitals across Africa and Asia to characterise drug-resistant infections by origin, clinical syndrome, patient age, outcome, and geographical location.</div></div><div><h3>Methods</h3><div>Patients were enrolled on selected wards and clinical data were collected daily for community-acquired infections (CAIs). Point prevalence surveys for hospital-acquired infections (HAIs) were conducted weekly. Mortality was assessed at discharge and after 28 days. Linked microbiology data were extracted from local laboratory databases. Primary descriptive analyses focused on WHO Global Antimicrobial Resistance and Use Surveillance System pathogen (target organism) bloodstream infections (BSIs). Comparisons were adjusted for clustering by site using random effects models.</div></div><div><h3>Findings</h3><div>Over 31 months, 41 907 infections were characterised from 41 032 admissions. Two-thirds were children (19 351; 47·2%) or neonates (6649; 16·2%). There were marked differences in pathogen incidence and antibiotic resistance when clinical infections were stratified by patient age category and infection origin (CAI/HAI). The highest rates of target organism AMR BSI were third-generation cephalosporin-resistant (3GC-R) <em>Escherichia coli</em> (718·56/100 000 blood cultured infection episodes), meticillin-resistant <em>Staphylococcus aureus</em> (586·89/100 000 blood cultured infection episodes), and 3GC-R <em>Klebsiella pneumoniae</em> (364·92/100 000 blood cultured infection episodes). In-hospital mortality was 13·1% (166/1265) in patients with target organism BSI versus 6·2% (1357/21 845) in those with negative blood cultures, p<0·0001.</div></div><div><h3>Interpretation</h3><div>ACORN2 has shown practical implementation of collecting linked clinical-laboratory AMR data in low-income and middle-income countries and identified a significant burden of WHO GLASS BSI. Adoption of the ACORN2 approach at scale might enhance use of diagnostic microbiology and improve the volume of clinical data included in national and global AMR surveillance datasets.</div></div><div><h3>Funding</h3><div>Wellcome.</div></div>","PeriodicalId":46633,"journal":{"name":"Lancet Microbe","volume":"7 1","pages":"Article 101228"},"PeriodicalIF":20.4,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145745136","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-01DOI: 10.1016/j.lanmic.2025.101222
Michael E DeWitt , Jennifer J Wenner , Brinkley R Bellotti , Joshua A Manuel , Cindy Toler , Elizabeth Palavecino , Candice J McNeil
{"title":"Promise and peril: doxycycline prophylaxis and the spread of resistance among diverse populations","authors":"Michael E DeWitt , Jennifer J Wenner , Brinkley R Bellotti , Joshua A Manuel , Cindy Toler , Elizabeth Palavecino , Candice J McNeil","doi":"10.1016/j.lanmic.2025.101222","DOIUrl":"10.1016/j.lanmic.2025.101222","url":null,"abstract":"","PeriodicalId":46633,"journal":{"name":"Lancet Microbe","volume":"7 1","pages":"Article 101222"},"PeriodicalIF":20.4,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144973758","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：